Bringing Patients Hope by Looking Ahead

Week in Review: Looking Ahead Brings Patients Hope

10.18.13 | By

Tuesday began Medicare Part D Open Enrollment. With the program still going strong 10 years after it was enacted, Part D represents a significant milestone for patients. Through December 7, 2013, seniors can enroll in the program or to switch to a new one, and with at least 23 options in every region of the United States, there are a variety of options to help patients get what they need. The rapidly changing, innovative environment in which our industry operates, however, means that we cannot just look at our past successes. To help patients live longer, healthier lives it is essential that we also look to the future.

We will be doing just that at our forum on Alzheimer’s disease next week. Alzheimer’s currently affects more than five million people in the U.S. and that number could increase to more than 13 million by 2050, which would have a tremendous effect on our health care system.  We must discuss the path forward to help protect patients and determine what can be done to develop solutions by 2025.

Thinking about the future of intellectual property (IP) is also essential to protecting patients. The Trans-Pacific Partnership (TPP) negotiations could conclude as early as this year, and one of the most important topics left to discuss is intellectual property. The need for strong IP is extremely important so that the biopharmaceutical industry can continue to develop new medicines for critical diseases like cancer, malaria and diabetes. The 12 countries involved in the TPP have more than 6,000 medicines currently in development that could improve the health of their citizens. If we do not take action today, their lives could be adversely affected.

As we look ahead, it is incredibly important that we continue to hold discussion about what the future should look like. The Alzheimer’s event will be a great discussion and yesterday’s Twitter chat hosted by Stephanie Fischer was a tremendous success with more than 160 participants contributing 730 tweets to the discussion. Be sure to follow our Twitter account for more updates about the future of the biopharmaceutical industry and to share your thoughts.


Hide Comments

More On PhRMA — powered by PhRMApedia


Cost in Context